HEPA Stock Overview A biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Hepion Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hepion Pharmaceuticals Historical stock prices Current Share Price US$0.32 52 Week High US$3.49 52 Week Low US$0.28 Beta 1.7 1 Month Change -34.33% 3 Month Change -50.70% 1 Year Change -84.75% 3 Year Change -98.39% 5 Year Change -99.68% Change since IPO -100.00%
Recent News & Updates
Hepion Pharmaceuticals Receives Written Notice from the Nasdaq Stock Market Jan 16 Hepion Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Dec 27
Pharma Two B Ltd. cancelled the acquisition of Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction. Dec 12
New major risk - Shareholder dilution Nov 29
Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit Nov 22
New major risk - Financial position Nov 17 See more updates
Hepion Pharmaceuticals Receives Written Notice from the Nasdaq Stock Market Jan 16 Hepion Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Dec 27
Pharma Two B Ltd. cancelled the acquisition of Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction. Dec 12
New major risk - Shareholder dilution Nov 29
Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit Nov 22
New major risk - Financial position Nov 17
Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Sep 05
High number of new and inexperienced directors Aug 15 Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million. Jul 22
Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing May 17
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial Apr 20 Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing Apr 02
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors Mar 06
New major risk - Share price stability Feb 15
Price target decreased by 27% to US$30.00 Feb 14
High number of new and inexperienced directors Feb 14
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors Feb 09 Hepion Pharmaceuticals, Inc. Announces CEO Changes
Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing Nov 15
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease Nov 14
New minor risk - Share price stability Nov 14
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice Oct 26
New minor risk - Shareholder dilution Oct 05 Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding Oct 05
Price target decreased by 46% to US$23.67 Oct 04
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat Sep 22
Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study Sep 15
Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023 Sep 09
New major risk - Financial position Aug 17
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely Aug 10
New major risk - Financial position Jul 02
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat Jun 16
Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial May 23
Price target decreased by 10% to US$62.67 May 16
High number of new directors May 04
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate Apr 25
Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma Jan 19
Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors Jan 13
Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements Dec 07
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial Dec 06
Price target decreased to US$2.50 Nov 16
Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate Oct 27
Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial Sep 13
Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial Sep 01
Hepion Pharma rises as company begins NASH treatment trial Aug 31
Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022 Jul 23
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely? Jul 04
Price target decreased to US$4.75 Jul 01
Hepion Pharmaceuticals, Inc. Announces Board Changes Jun 29
Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer Jun 15
Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq Jun 07
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial May 04
Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022 May 02 Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing Apr 01
Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH Feb 17
Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia Feb 16
Hepion Pharmaceuticals: Facing The Momentous Year 2022 Jan 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer Dec 22
Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug Sep 21
Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth Sep 14
Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race Sep 08
Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints Jul 15
Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video) May 26
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH May 07
Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million. Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry? Feb 18
Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer Feb 11
New 90-day high: US$2.98 Feb 09
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH Dec 30
Hepion Pharma cleared to advance final dosing cohort in NASH trial Dec 29
Hepion Pharma to begin CRV431 testing in COVID-19 patients Dec 22
Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study Dec 10
Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease Dec 03
Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Nov 27
Hepion Pharma prices equity offering at $1.50 Nov 25
Hepion Pharmaceuticals Terminated the At Market Issuance Sales Agreement with B. Riley FBR, Inc Nov 21
Hepion Pharmaceuticals, Inc.'s Data Safety Monitoring Board Recommends Continuation of Phase 2A 'Ambition' Clinical Trial for Treatment of Advanced Nash Nov 19
New 90-day low: US$2.68 Nov 18
Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow Oct 31 Shareholder Returns HEPA US Pharmaceuticals US Market 7D -32.3% 0.4% 3.8% 1Y -84.7% 1.4% 24.4%
See full shareholder returns
Return vs Market: HEPA underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is HEPA's price volatile compared to industry and market? HEPA volatility HEPA Average Weekly Movement 16.5% Pharmaceuticals Industry Average Movement 10.7% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: HEPA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HEPA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Show more Hepion Pharmaceuticals, Inc. Fundamentals Summary How do Hepion Pharmaceuticals's earnings and revenue compare to its market cap? HEPA fundamental statistics Market cap US$3.26m Earnings (TTM ) -US$22.70m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HEPA income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$22.70m Earnings -US$22.70m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.26 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -517.8%
How did HEPA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 05:03 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hepion Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Kumaraguru Raja Brookline Capital Markets Kristen Kluska Cantor Fitzgerald & Co.
Show 5 more analysts 
